The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Latham & Watkins LLP

Alan Mendelson

Work 6504634693
Latham & Watkins LLP


Alan Mendelson represents emerging and public growth companies, primarily in the life sciences industry. He served as the Co-chair of the firm’s Emerging Companies Practice from 2001 to 2013 and currently is Co-chair of the Life Sciences Industry Group. Mr. Mendelson has handled and supervised a variety of major business transactions.


United States: Industry focus

Healthcare: life sciences

Within: Leading lawyers

Alan Mendelson - Latham & Watkins LLP

Within: Healthcare: life sciences

Considered by clients as ‘superior’, Latham & Watkins LLP's life sciences practice stands out for its ‘expertise, breadth of capabilities, diligence and customer focus’. Washington DC’s regulatory expert John Manthei acted for pharmaceutical manufacturer Alvogen, obtaining a temporary restraining order preventing the State of Nevada from using medication distributed by the client in an execution. Manthei and Ben Haas (who is also based in Washington DC) assisted Endo and its subsidiary Par Sterile Products with a challenge to FDA’s implementation of the 2013 Drug Quality and Security Act (DQSA) in relation to the regulation of pharmaceutical compounding by outsourcing facilities. Silicon Valley’s Alan Mendelson represents emerging and public growth life sciences companies in a number of business transactions, including M&A, private placements and public offerings. The ‘fully engaged and very accessible’ Nathan Ajiashvili, who is based in New York and specializes in capital markets, and Washington DC’s associate Eitan Bernstein are also recommended.

[back to top]

United States: M&A/corporate and commercial

Shareholder activism

Within: Shareholder activism

Latham & Watkins LLP regularly acts for company boards in the defense of activist campaigns. Mark Gerstein and Christopher Drewry in Chicago, and Scott Herlihy in Washington DC, advised Owens-Illinois on an activist campaign brought by Atlantic Investment Management. Gerstein and Michael Dillard in Houston advised QEP Resources on an investment in the company by Elliott Management. In Silicon Valley, Tad Freese and Josh Dubofsky acted for e.l.f. Beauty in its relations with Marathon Partners, while Dubofsky, Ruck, Mark Roerder and Alan Mendelson advised Mellanox Technologies on its relationship with Starboard Value. Other clients include Aratana Theraputics and, the latter of which the team advised on an investment in Starboard Value by Drewery, Aslani Far and Gerstein. Other key figures include Dennis Craythorn and Adel Aslani-Far in New York, Peter Handrinos in Boston, and Patrick Pohlen in Silicon Valley, the last of whom advised Calix on a campaign brought by Voce Capital Management.

[back to top]

Venture capital and emerging companies

Within: Venture capital and emerging companies

International law firm Latham & Watkins LLP's 'practical and responsive' team has a strong focus on the start-up, emerging company and venture capital sectors, and is well known for advising clients on the whole life-cycle of an emerging company. Recent work for the group includes advising Crinetics Pharmaceuticals, a rare-disease therapeutics company, on its $63.5m Series B financing. The client roster includes Ginkgo BioWorks, ArcherDX, 4D Molecular Therapeutics and Impossible Foods. Key partners include Alan Mendelson, who is global chair of the life sciences industry group, and John Chory and Benjamin Potter, who share leadership of the emerging companies practice. Patrick Pohlen is also recommended.

[back to top]

Back to index

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to